Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02513667 · ClinicalTrials.gov registry record · Phase 2
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT02513667 is a Phase 2 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT02513667, a Phase 2 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to see if Ceritinib can target ALK in non-small cell lung cancer and slow down cancer growth and prevent it from spreading.
Interventions
- DRUG Ceritinib
- RADIATION Stereotactic ablative body radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-11 |
| Est. Completion | 2021-05-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02513667
The ClinicalTrials.gov registry entry for NCT02513667 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ceritinib is the first listed.
NCT02513667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02513667 about?
NCT02513667 is a clinical study titled "Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma". The purpose of this study is to see if Ceritinib can target ALK in non-small cell lung cancer and slow down cancer growth and prevent it from spreading.
What is the current status of trial NCT02513667?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2015-11. Estimated completion is 2021-05-29.
What interventions are being tested in trial NCT02513667?
The interventions under investigation include: Ceritinib (DRUG), Stereotactic ablative body radiation (RADIATION).
Who is sponsoring clinical trial NCT02513667?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.